Α



Figure S1

Wasting disease in $miR-223^{-/-}$ mice infected with *Mtb* in absence of increased bacterial dissemination. (A) Body weights of C57BL/6 (WT) and $miR-223^{-/-}$ mice recorded at various time-points following infection. Data are presented as mean ± SEM and results are representative of two independent experiments, ANOVA with Bonferroni post-test, (n=10). (B) Bacterial loads in spleens of WT and $miR-223^{-/-}$ mice. Data are presented as median ± iQR and results are representative of three independent experiments (n=5-6). **p<0.01, ***p<0.001.



Cellular and molecular immune parameters in *Mtb*-infected C57BL/6 (WT) and *miR-223^{-/-}* mice. (A) qRT-PCR of chemokine and cytokine genes in respiratory parenchyma. *Gapd* was used as reference gene and data were normalized to uninfected mice. Data are presented as mean \pm SEM and are representative of two independent experiments, Student's t-test (n=9–11). (B,C) Protein concentrations of Cxcl9, Cxcl10, Cxcl1 and IFN- γ were measured using multiplex immunoassay in lung homogenates collected at 21 days p.i. Data are presented as mean \pm SEM and are pooled from four independent experiments, ANOVA with Bonferroni posttest (n=18–24). (D) Serum concentration of immune mediators. Data are presented as mean \pm SEM and are representative of two independent experiments, Student t-test (n=3). (F) Immunohistochemistry for inducible NOS (iNOS) and myeloperoxidase (MPO) in lung tissue of *miR-223^{-/-}* mice at 25 days p.i. Pictures are representative of two independent experiments (n=3). Scale bar: 10 µm. * p<0.05, **p<0.01, ***p<0.001.



Figure S3 Western blot for total IKK α and β -actin in lung homogenates from C57BL/6 (WT) and *miR-223*^{-/-} mice at 21 days p.i. Data are representative of two independent experiments (n=5).

Flow cytometry experiments



Figure S4

Gating strategies applied for **(A)** identification of innate cell populations: AMs [leukocyte gate (R1)⁺ CD11c^{hi}CD11b⁻], PMNs [leukocyte gate (R1)⁺ Ly6G^{hi}CD11b^{hi}], lung macrophages [leukocyte gate (R1)⁺ CD11c⁻Ly6G⁻ F4/80⁺CD11b⁺], iMs [leukocyte gate (R1)⁺ CD11c⁻Ly6G⁻ F4/80⁺CD11b⁺ Ly6C^{hi}] and **(B)** sorting of innate cell populations: AM [leukocyte gate (R1)⁺ CD11c^{hi}CD11b⁻], PMNs [leukocyte gate (R1)⁺ NOT(AM)⁺ Ly6G^{hi}CD11b^{hi}], lung macrophages [leukocyte gate (R1)⁺ NOT(AM)⁺ NOT(PMN)⁺ CD11c⁻Ly6G⁻ F4/80⁺CD11b⁺], iMs [leukocyte gate (R1)⁺ NOT(AM)⁺ NOT(PMN)⁺ CD11c⁻Ly6G⁻ F4/80⁺CD11b⁺]].



Cell death events in lungs of WT (C57BL/6) and miR-223 \neg mice during TB. Lung tissue collected at day 21 p.i. was TUNEL-stained (Roche) to evaluate the proportion of apoptotic cells in situ. Pictures are representative of two independent experiments (n=5). Scale bar: 100 µm.



MiR-223 does not target the chemokines Cxcl9 and Cxcl10. (A) Luciferase activity of HeLa cells transfected with 3'UTR of *cxcl9* plus scramble and miR-223 mimics. (B) Luciferase activity of HeLa cells transfected with 3'UTR of *cxcl10* plus scramble and miR-223 mimics. Data are presented as mean \pm SEM and results are representative of three experiments with three replicates each.



CXCR2 cell surface expression on PMNs. PMNs from C57BL/6 (WT) and $miR-223^{-/-}$ mice were purified from the bone marrow and stained for CXCR2 followed by analysis by FACS. Numbers represent the mean fluorescence \pm SEM (n=4) Data are representative of two experiments with four replicates each.





Treatment with mAB against Ly6G affects the expression of genes targeted by *miR-223* during TB. **(A)** *MiR-223* -/- mice were treated with mAb against Ly6G (PMN-specific) or with control IgG. PMN frequency was evaluated by analysis of blood smears at indicated times p.i. Data are presented as mean \pm SEM and are representative of two independent experiments, ANOVA with Bonferroni post-test (n=3). **(B)** C57BL/6 (WT) mice were treated with mAb against Ly6G (PMN specific) or with control IgG. PMN frequency was evaluated by analysis of blood smears at indicated times p.i. Data are presented as mean \pm SEM, ANOVA with Bonferroni post-test (n=3). **(B)** C57BL/6 (WT) mice were treated with mAb against Ly6G (PMN specific) or with control IgG. PMN frequency was evaluated by analysis of blood smears at indicated times p.i. Data are presented as mean \pm SEM, ANOVA with Bonferroni post-test (n=3). **(C)** *Cxcl2*, *II-6* and *Ccl3* were quantified using qRT-PCR in lung tissue collected at 25 days p.i. from C57BL/6 (WT) and *miR-223*^{-/-} mice treated as indicated. U6 snRNA was used as reference gene and data were normalized to uninfected mice. Data are presented as mean \pm SEM and are representative of two experiments (n=3–5). **(D, E)** Immunohistochemistry for neutrophils and inflammatory monocytes/macrophages (MPO) in the lung tissue collected at day 25 p.i. Data are representative of two independent experiment (n=5). Scale bar 100 μ m. * p<0.05, **p<0.01, ***p<0.001.





Flow cytometric analysis of lung cells upon PMN-specific treatment. Mice were treated with control antibody (control) or PMN-specific Ly6G mAb (1A8) and consequently lung tissue was processed for flow cytometric investigations. Representative dot plots indicate the effect of the treatment on lung PMN frequency (n=5). Data are representative of two experiments.



Frequencies of blood PMNs during TB in $miR-223^{-/-}$ and $Cxcr2^{-/-}miR-223^{-/-}$ mice. Blood was processed for haematologic analysis at 12 and 24 days p.i. Data are presented as mean ± SEM and are from one experiment. ANOVA with Bonferroni post-test (n=3). **p<0.01.



Proposed model for miR-223 activity during *Mtb* infection. MiR-223 fine-tunes myeloid cell activation during *Mtb* infection by modulating NF-κB activation, and thus in mononuclear cells, primarily controls gene transcription. In addition miR-223 targets II-6 and the chemokines Cxcl2 and Ccl3 post-transcriptionally: in this way miR-223 affects PMN dynamics at the site of mycobacterial infection.

Primary sequence name	Fold change	P value
hsa-miR-335*	4.58655	0.00007
hsa-miR-197	2.39823	0.00007
hsa-miR-223	1.71582	0.00192
hsa-miR-625	1.54236	0.03436
hsa-miR-22	1.47565	0.04672
hsa-miR-629	1.35915	0.04027
hsa-miR-451	-1.03788	0.045936
hsa-miR-148b	-1.49055	0.04583
hsa-miR-19b	-1.61769	0.00312
hsa-miR-501-3p	-1.73841	0.0032
hsa-miR-940	-1.83695	0.00956
hsa-miR-296-5p	-1.87385	0.00145
hsa-miR-33b*	-2.07159	0.03662
hsa-miR-92b	-2.83205	0.01852
hsa-miR-744	-3.28177	0.00065
hsa-miR-1238	-4.07883	0.00032

Table S1

Differentially regulated mRNAs in whole blood of active TB patients compared to healthy latent TB-infected individuals.

		- ·		miR-223 predicted
Fold change	P value	Primary sequence name	Accession #	target
74.92	2.15 E-07	Hrnr	NM_133698	N
74.40	1.67 E-07	Serpinb3b	NM_198680	Y
38.75	0.00007	Myot	NM_021484	N
37.34	7.84 E-10	Sprrl5	NM_026822	N
36.25	4.85 E-08	Krt2-4	NM_008475	N
35.78	0.00003	Crisp1	NM_009638	N
33.76	1.44 E-07	Sprr3	NM_011478	N
31.17	5.86 E-10	Calm4	NM_020036	N
30.72	9.08 E-10	ll1f6	NM_019450	N
27.79	1.71 E-09	Serpinb3a	NM_009126	N
27.70	5.72 E-07	Krt1-13	NM_010662	N
25.47	9.35 E-07	Myh4	NM_010855	N
25.04	1.48 E-09	Dmkn	NM_172899	Y
23.97	1.51 E-09	Asah3	NM_175731	N
22.16	2.90 E-11	Mt4	NM_008631	N
21.79	0.00021	Serpinb5	NM_009257	N
21.46	0.00045	Klk7	NM_011872	Y
21.21	1.98 E-09	Serpinb3c	NM_201363	Y
19.88	2.47 E-09	Hrnr	NM_133698	N
18.34	6.57 E-08	Pkp1	NM_019645	Y
15.33	0.00003	Gpr87	NM_032399	N
15.26	1.56 E-09	Serpinb3a	NM_009126	N
14.01	0.00098	Sprrl1	NM_033175	N
14.00	6.97 E-09	Myh8	NM_177369	Ν
12.55	1.52 E-12	Sprrl7	NM_027137	Ν
12.16	1.19 E-07	Dsc1	NM_013504	N
12.10	8.52 E-06	Pla2g4e	NM_177845	Ν
11.41	1.09 E-07	Myh2	NM_144961	N
10.88	8.35 E-07	Pvalb	NM_013645	N
9.79	1.22 E-12	Sprrl9	NM_026335	N
9.48	3.85 E-12	Sim2	NM_011377	N
7.09	7.40 E-07	Jsrp1	NM_028001	N
6.69	2.99 E-09	Alox12b	NM_009659	N
6.56	6.63 E-09	ll1f5	NM_019451	Y
6.44	0.00028	Them5	NM_025416	N
5.32	0.00023	Gsdm1	NM_021347	N
5.29	3.74 E-12	Tbx15	NM_009323	Y
5.10	1.32 E-29	Cyp1a1	NM_009992	N
4.67	0.00011	Casq1	NM_009813	N
4.45	0.00002	Hsd17b2	NM_008290	N
4.16	0.00011	S100a15	NM_199422	N
3.40	0.0008	Defb6	NM_054074	N
3.39	0	Ces1	NM_021456	Y
3.36	0	Ces1	NM_021456	Y
3.33	0.00074	Smtnl1	NM_024230	N
3.11	0.00029	Cdsn	NM_001008424	N
3.10	1.44 E-07	Mybph	NM_016749	Ν
2.56	0.00046	Prom2	NM_138750	Ν
2.26	0.00002	Cpa4	NM_027926	Y
2.14	0.00016	Pdk4	NM_013743	Y
2.10	2.43 E-10	ll1f9	NM_153511	Ν
2.03	0.00004	Myom2	NM_008664	N

Table S2

List of upregulated genes in lung tissue of $miR-223^{-/-}$ mice at day 14 post-*Mtb*-infection.

				miR-223 predicted
Fold change	P value	Primary sequence name	Accession #	target
9.93	2.36 E-06	Cxcl2	NM_009140	Y
7.56	0.00009	Olfr633	NM_146354	Ν
7.13	5.86 E-11	Retnlb	NM_023881	Ν
6.96	7 41 E-23	ll1f9	NM 153511	Ν
6.00	5.54 E 42	Cof3	NM_000071	× ×
0.90	5.54 E-42	CSI3	NIVI_009971	1 X
6.70	2.84 E-11	UCI3	NM_011337	Ŷ
6.60	1.55 E-10	Olfm4	NM_001030294	N
6.08	6.27 E-14	Mmp10	NM_019471	N
5.82	0.00042	Myh4	NM_010855	Ν
5.78	1.46 E-13	ll11	NM 008350	Ν
5.42	9.86 E-17	Gzmf	NM_010374	Ν
5 40	3 66 E-11	Trem1	NM 021406	Y
5.40	1 40 E-12	Olfm4	NM 001030294	N
5.40	1.40 E-12	Cold	NM 012652	N
5.25	2.94 E-11		NNI_013032	IN N
5.18	3.57 E-08	Orm2	NM_011016	N
4.64	1.19 E-06	Orm1	NM_008768	N
4.33	3.91 E-06	Grem1	NM_011824	Y
4.33	3.16 E-10	116	NM_031168	Y
4.14	2.20 E-07	BC055107	NM_183187	Ν
4.02	0.00039	Pou5f1	NM 013633	Ν
3 95	1 84 F-12	Scra1	NM_009136	Ν
3.88	9.31 E-10	Dmbt1	NM 007769	N
3.00	9.91 2-10		NM_000014	IN NI
3.07	0.00003		NIVI_000614	IN .
3.87	5.66 E-15	Infrst23	NM_024290	N
3.85	8.60 E-36	Hspa1a	NM_010479	Y
3.82	2.12 E-14	Hspa1a	NM_010479	Y
3.79	8.21 E-10	Gpr109a	NM_030701	N
3.69	4.82 E-07	ll1f6	NM_019450	Ν
3.64	5.35 E-27	Arg1	NM 007482	Ν
3.62	3 71 E-07	Ms4a3	NM 133246	Ν
3.55	0.00078	Stfo3	NM_025288	N
3.35		Sila5	NM 422200	IN NI
3.49	1.20 E-00	Kila I7	NIVI_133203	IN .
3.43	0	1122	NM_016971	N
3.40	0	Orm3	NM_013623	N
3.30	7.89 E-06	Gm1960	NM_203320	N
3.29	0	Hspa1a	NM_010479	Y
3.29	3.77 E-24	Etos1	NM_053258	Ν
3.29	2.94 E-11	Stfa1	NM_001001332	Ν
3.24	0	1122	NM 016971	Ν
3 20	0 00008	Stfa1	NM 001001332	Ν
3 17	0.0001	Slfn3	NM 011409	N
2.17	0.0001	Sornino2m	NM 000252	N
3.14	0.00005	Serpinasin Cocom10	NM 007675	N
3.06	0.23 E-00	Ceacamito	NIVI_007675	ł
3.01	0,00009	AKr1c14	NM_134072	N
3.00	1.16 E-35	Ngp	NM_008694	N
2.97	2.14 E-11	Saa1	NM_009117	N
2.96	0.00008	Stfa1	NM_001001332	N
2.95	1.75E-07	Saa2	NM_011314	Ν
2.86	0.00021	ll1rn	NM 031167	Ν
2.84	0.00003	Retnla	NM 020509	Ν
2 79	0.00006	Retnla	NM_020509	N
2.70	1 30 E 20	Trom1	NM_021406	~
2.79	1.39 E-20	NHO	NM 000000	1 X
2.75	0.00016	Mt2	NIVI_008630	ř
2.69	0.00048	Onecut2	NM_194268	Ŷ
2.68	1.75 E-14	Fosl1	NM_010235	N
2.68	1.06 E-22	Slpi	NM_011414	Ν
2.66	0.00001	ltgb2l	NM_008405	Ν
2.61	1.26 E-18	Ctsg	NM_007800	Ν
2.57	0.00002	Lphn3	NM 198702	Y
2 53	1.35 E-07	Cd14	NM 009841	Ν
2 53	0	Rhov	NM 145530	Y
2.00	0 70 E 10	Dram1	NIM_001002042	N
2.00	J.12 E-12	Fidilii		IN NI
2.47	4.55 E-U/	Sectimit		IN N
2.47	0.47 E-24	Hspala	NM_010479	Y
2.47	2.17 E-10	Osm	NM_001013365	Y

2.46	3.76 E-18	Mxd1	NM_010751	Y
2.41	4.26 E-06	Ptprn	NM_008985	Ν
2.41	3.63 E-09	Map3k6	NM_016693	Ν
2.40	9.80 E-08	Saa3	NM_011315	Ν
2.40	0.00006	Syt8	NM_018802	Ν
2.37	0.00005	Saa4	NM_011316	Ν
2.36	4.43 E-08	Map3k6	NM_016693	Ν
2.36	0.000233	Ccl2	NM_011333	Y
2.36	0.00038	Рарра	NM_021362	Y
2.34	1.90 E-07	F13a1	NM_028784	Ν
2.34	1.67 E-07	Ptx3	NM_008987	Ν
2.33	2.38 E-10	Serpina3n	NM_009252	Y
2.28	4.67 E-22	TIr6	NM_011604	Y
2.27	1.61 E-10	Saa1	NM_009117	Ν
2.24	2.78 E-06	Ltf	NM_008522	Ν
2.24	0.00002	Ltf	NM_008522	Ν
2.23	3.97 E-10	Pdzd3	NM_133226	Ν
2.23	1.24 E-04	Cxcl9	NM_008599	Y
2.22	2.78 E-29	G0s2	NM_008059	Y
2.21	0.0008751	Cxcl10	NM_021274	Y
2.20	0.0001	Inhba	NM_008380	Ν
2.19	1.66 E-09	Bcl2l11	NM_207680	Y
2.19	0.00007	Prtn3	NM_011178	Ν
2.18	0.00041	Acsl6	NM_144823	Ν
2.17	6.11 E-20	Osm	NM_001013365	Y
2.16	0.00016	MGC58177	NM_198666	Ν
2.16	0.00031	Fpr1	NM_013521	Ν
2.15	3.32 E-08	Aldh1a3	NM_053080	Y
2.14	1.24 E-11	Arg2	NM_009705	N
2.13	5.60 E-06	lfng	NM_008337	Y
2.13	0.00081	Serpinb2	NM_011111	N
2.13	9.66 E-07	Pla1a	NM_134102	Ν
2.13	4.46 E-06	Mybph	NM_016749	Ν
2.12	1.91 E-09	Sult1a1	NM_133670	Y
2.12	5.85 E-07	Мро	NM_010824	Ν
2.10	1.05 E-09	Sectm1	NM_026907	N
2.10	0.00022475	Cxcl1	NM_008176	Y
2.10	0.00012	Speer4a	NM_029376	N
2.09	2.05 E-30	Ltb4r1	NM_008519	N
2.09	1.35 E-25	Has1	NM_008215	N
2.09	3.59 E-07	Timp1	NM_011593	N
2.08	4.42 E-35	Wdfy1	NM_027057	N
2.07	9.84 E-06	Sphk1	NM_025367	N
2.05	0.00028	Ces6	NM_133960	N
2.05	1.74 E-06	Gda	NM_010266	N
2.05	1.25 E-12	SIc5a9	NM_145551	N
2.05	8.41 E-07	Speer4d	NM_025759	N
2.05	5.59 E-06	Fkbp5	NM_010220	Y
2.04	0.00003	Cxcl13	NM_018866	Ν
2.04	2.62 E-16	Mefv	NM_019453	Ν
2.04	1.52 E-09	Chl1	NM_007697	Y
2.03	1.13 E-30	Rnf36	NM_080510	N
2.02	1.55 E-09	Timp1	NM_011593	Ν
2.01	6.05 E-06	Dio2	NM_010050	Y
2.01	1.12 E-10	Sphk1	NM_025367	Ν
2.01	0.00026	Tnc	NM_011607	Ν
2.01	7.95 E-06	Ptx3	NM_008987	Ν

Table S3

List of upregulated genes in lung tissue of $miR-223^{-/-}$ mice at day 21 post-infection.

Lung tissue^a

Gene name ^b	Mouse genotype	Day 7	Day 14	Day 21
<i>lmo2</i> ⁽³⁹⁾	WT	0.89 ± 0.11	1.00 ± 0.18	0.62 ± 0.26
	miR-223 ^{-/-}	0.78 ± 0.11	0.81 ±0,12	0.55 ± 0.42
<i>mef2c</i> ⁽²⁴⁾	WT	1.26 ± 0.27	1.16 ± 0.07	0.46 ± 0.08
	miR-223 ^{-/-}	1.24 ± 0.07	1.15 ± 0.13	0.35 ± 0.08
ikk-a ⁽²⁶⁾	WT	0.72 ± 0.05	0.80 ± 0.10	0.53 ± 0.16
	miR-223 ^{-/-}	0.84 ± 0.10	0.84 ± 0.09	0.39 ± 0.03
<i>CEBP-b</i> ⁽³⁹⁾	WT	0.34 ± 0.19	0.64 ± 0.32	0.58 ±0.20
	miR-223 ^{-/-}	0.61 ± 0.18	0.84 ± 0.68	0.89 ± 0.27

^a Fold change value normalized using *Gapd* and compared to uninfected samples. Data are representative of 2 independent experiments with 5 animals/group.

^b Predicted miR-223 target (see references)

Table S4

Transcriptional activity of known *miR*-223 targets in lung tissue of C57BL/6 (WT) and *miR*-223^{-/-} mice during TB. qRT-PCR of *Imo2*, *mef2c*, *ikka*, and *CEBP-* β in lung parenchyma at different time points during TB.

Primer name	Primer sequence 5'→3'
CXCL2 3'UTR For	CTCGAG ¹ gcctttaagatacccactaaca
CXCL2 3'UTR Rev	GCGGCCGC ² acatgaataaataaatgtgtcca
CCL3 3'UTR For	CTCGAG ¹ gagtcttggaggcagcgaggaacccc
CCL3 3'UTR Rev	GCGGCCGC ² gcatatttattacttctctgg
IL6 3'UTR For	CTCGAG ¹ tgcgttatgcctaagcatatc
IL6 3'UTR Rev	GCGGCCGC ² acattataaaaatacatcacaaag
CXCL9 3'UTR For	CTCGAG ¹ agaccattactttaccaacaag
CXC9 3'UTR Rev	GCGGCCGC ² gaatttagtgcacttttactga
CXCL10 3'UTR For	CTCGAG ¹ ctggagtgaagccacgcaca
CXCL10 3'UTR Rev	GCGGCCGC ² gtctcctacccaccccaacttct
CXCL2 mut 1	gggggtggggacacctaccugcagtcggatggct
CXCL2 mut 2	agccatccgactgcaggtaggtgtccccaccccc
CCL3 mut 1	tgatgacaaagtcatgggctttcaaatgtacaatagatgct
CCL3 mut 2	agcatctattgtacatttgaaagcccatgactttgtcatca
IL6 mut 1	atgttgttctctacgaagcccggatagttgggacactatttt
IL6 mut 2	aaaatagtgtcccaactatccgggcttcgtagagaacaacat

¹ Xhol restriction sequence

² Notl restriction sequence

Table S5

Primers used for generation of 3'-UTR luciferase reporter constructs.